Abstract:Wickerhamomyces anomalus has been previously classified as Hansenula anomala, Pichia anomala, and Candida pelliculosa and was recently reclassified in the genus Wickerhamomyces after phylogenetic analysis of its genetic sequence. An increasing number of reports of human infections by W. anomalus have emerged, suggesting that this microorganism is an emerging pathogen. The present review aimed to provide data on the epidemiology, antifungal resistance, clinical characteristics, treatment, and outcomes of fungemia by W. anomalus by extracting all the available information from published original reports in the literature. PubMed/Medline, Cochrane Library, and Scopus databases were searched for eligible articles reporting data on patients with this disease. In total, 36 studies involving 170 patients were included. The age of patients with fungemia by W. anomalus ranged from 0 to 89 years; the mean age was 22.8 years, the median age was 2.2 years, with more than 37 patients being less than one month old, and 54% (88 out of 163 patients) were male. Regarding patients' history, 70.4% had a central venous catheter use (CVC), 28.7% were on total parenteral nutrition (TPN), 97% of neonates were hospitalized in the neonatal ICU (NICU), and 39.4% of the rest of the patients were hospitalized in the intensive care unit (ICU). Previous antimicrobial use was noted in 65.9% of patients. The most common identification method was the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in 34.1%, VITEK and VITEK 2 in 20.6%, and ID32 C in 15.3%. W. anomalus had minimal antifungal resistance to fluconazole, echinocandins, and amphotericin B, the most commonly used antifungals for treatment. Fever and sepsis were the most common clinical presentation noted in 95.8% and 86%, respectively. Overall mortality was 20% and was slightly higher in patients older than one year. Due to the rarity of this disease, future multicenter studies should be performed to adequately characterize patients' characteristics, treatment, and outcomes, which will increase our understanding and allow drawing safer conclusions regarding optimal management.

Malassezia spp. Yeasts of Emerging Concern in Fungemia

Part 1: Understanding the role of Malassezia spp. in skin disorders: Malassezia yeasts as commensal or pathogenic organisms of human and animal skin

Malassezia: Zoonotic Implications, Parallels and Differences in Colonization and Disease in Humans and Animals

Overview of the Potential Role of Malassezia in Gut Health and Disease

Many ways, one microorganism: Several approaches to study Malassezia in interactions with model hosts

Approaches for Genetic Discoveries in the Skin Commensal and Pathogenic Malassezia Yeasts

Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment

Malassezia Yeasts in Veterinary Dermatology: An Updated Overview

Chronic Diseases Associated with Malassezia Yeast

Malassezia species in skin diseases

Azole Resistance Mechanisms in Pathogenic Malassezia furfur

Possible plant-based solutions for skin yeast infections

Skin Commensal Fungus Malassezia and Its Lipases

Malassezia furfur folliculitis in cancer patients. The need for interaction of microbiologist, surgical pathologist, and clinician in facilitating identification by the clinical microbiology laboratory

Immunology of Diseases Associated with Malassezia Species

Fungemia by Wickerhamomyces anomalus—A Narrative Review

[Yeast-like fungi malassezia (pityrosporum): clinical and immunological aspects fo study]

Malassezia restricta as an unexpected cause of infectious osteomyelitis diagnosed by metagenomic sequencing: a case report and literature review

Cutaneous Malassezia: Commensal, Pathogen, or Protector?

A greener side of health care: Revisiting phytomedicine against the human fungal pathogen Malassezia

Malassezia‐associated skin diseases in the pediatric population